

CURRENT REPORT 19/2024

May 29, 2024

Obtaining the status of Associate Partner within IPCEI Med4Cure

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("**Company**") announces that on May 28, 2024, it has received information that the European Commission has approved the first Important Project of Common European Interest ('IPCEI') to support research, innovation and the first industrial deployment of healthcare products, as well as innovative production processes of pharmaceuticals. As part of the approved "IPCEI Med4Cure" project, jointly notified by six member states - Belgium, France, Spain, Slovakia, Hungary and Italy - the Company was officially announced as one of 11 and the only Associated Partner from Poland.

The Associated Partner status is the result of a successful selection at the national level in a targeted call for innovative projects in the field of health organized by the Ministry of Development and Technology. The subject of the project submitted by the Company under the working name PANACEA-NOVO to IPCEI Med4Cure is the creation of a unique platform for the discovery of new therapeutic targets with potential in the treatment of rare cancers, combined with several early discovery campaigns for innovative drugs.

The European Commission's decision to grant the Company Associate Partner status does not yet mean that the Company has been granted financing. Obtaining the above status means that the Company has been qualified for the final stage of the process, which will be participation in a dedicated call at the national level. The results of the call will be a final decision on the terms, scope and intensity of funding. The date for the announcement of the call has not yet been set.

The Company expects the total costs of the project to be submitted to the call will amount up to PLN 142.5 million. At this stage, the Company expects that the majority of project activities will meet the criteria for industrial research, for which the funding intensity in similar projects is about 75-80%. The Company estimates that the project may start in 2025 and will last between 60 to 72 months.

The Company's Management Board expects that most of the work in the project will be performed by current employees and does not anticipate a significant increase in employment related to the PANACEA-NOVO project.

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Art. 17.1 of MAR

Representatives of the Company:

- Paweł Przewięźlikowski – President of the Management Board
- Kamil Sitarz – Member of the Management Board